Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Parkinson's Disease Psychosis
2019-003623-37Phase 2Unknown
- Sponsor
- King's College London
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cannabidiol in Parkinson's disease (PD), sponsored by King's College London. Primary endpoint: Maximum tolerated dose of cannabidiol. Status: unknown.
02
Drugs
cannabidiol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2019-003623-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003623-37.